Abstract. The chaperonin-containing T-complex protein 1 (CCT) has eight subunits, CCT 1-8, which are dysregulated in several types of cancer. To determine how subunit 8 (CCT8) influences the development of esophageal squamous cell carcinoma (ESCC), immunohistochemistry and western blot analysis were performed on 128 ESCC samples in the present study to measure the expression of CCT8. The prognostic value of CCT8 was analyzed using univariate and multivariate survival analyses. CCT8 knockdown in ESCC cells was performed and subsequently, the migration and invasion of ESCC cells was assessed. The results of immunohistochemistry and western blot analysis of ESCC tissue indicated that the expression of CCT8 in tumor tissues from patients with lymph node metastasis (LNM) was high whereas its expression in tissues from those without LNM was low. In addition, the overall survival rate of patients with high CCT8 expression was poor. It was demonstrated that CCT8 influenced the migration and invasion of ESCC cells by regulating α-actin and β-tubulin. Following CCT8 knockdown, cells were treated with cisplatin; it was demonstrated that α-actin and β-tubulin were downregulated and that cell apoptosis was enhanced. These data confirm that α-actin and β-tubulin are regulated by CCT8, and that increased CCT8 expression is associated with poor patient prognosis and cisplatin resistance in ESCC.
Introduction
Esophageal squamous cell carcinoma (ESCC) is a type of malignant gastroenterological tumor with a high incidence in China (1) . ESCC tumors readily undergo metastasis and this is the primary explanation for the poor prognosis of patients with ESCC (2) . Cancer metastasis is associated with compound mechanisms, sunch as epithelial-mesenchymal transition (EMT). The expression of E-cadherin, an epithelial marker, is decreased in EMT (3) . It is important to determine the process by which ESCC tumors undergo metastasis, in order to improve the diagnosis of patients with ESCC and develop effective therapeutic strategies to treat this disease (4) .
It has been demonstrated that oncogenes are associated with tumorigenesis, such as epidermal growth factor receptor (EGFR), cyclin D1 and p53 (5) . The chaperonin containing T-complex protein 1 (CCT) contains eight different subunits, . CCT is required to stimulate the folding of actin, tubulin and other cytosolic proteins (7, 8) and is involved in mediating various biological processes, including cytoskeletal organization (9) (10) (11) , cell cycle progression (9, 11) and apoptosis (12) . Yokota et al (13) initially identified CCT as an oncogene; they reported that CCT was highly expressed in liver and colon cancer. It has since been demonstrated that CCT expression is correlated with the growth of mammary carcinoma cells (14, 15) . Several studies have indicated that CCT, particularly subunit 8 (CCT8) serves an important role during the progression of tumors, including B-cell non-Hodgkin's lymphoma (16) , glioma (17) and hepatocellular carcinoma (18) . However, to the best of our knowledge, the expression of CCT8 in ESCC and the role it serves remain unclear.
The goal of the present study was to determine the association between CCT8 and ESCC and assess the feasibility of using CCT8 as a novel prognostic indicator in ESCC. The functional role of CCT8 in the migration and invasion of ESCC cells was examined following transfection with small interfering (si)RNA to induce CCT8 knockdown. The results The three human ESCC cell lines ECA109, TE1 and KYSE30 were purchased from the China Academy of Science cell library (Beijing, China). Cells were cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.), penicillin (100 U/ml) and streptomycin (100 µg/ml) at 5% CO 2 and 37˚C. In cisplatin-related experiments, TE-1 cells were seeded onto 6-well cell culture cluster plates (Corning inc, Corning, NY, USA) at a concentration of 1x10 6 cells/well in 2 ml culture medium. After being grown overnight, the cells were treated with cisplatin (cat. no., CAS 15663-27-1, Santa Cruz Biotechnology, Inc., Dallas, TX, USA) at various concentrations (0-50 µM) for 48 h.
Chaperonin-containing T-complex

Immunohistochemistry (IHC)
. IHC was performed following a previously described protocol (20) . The primary antibodies used were anti-CCT8 (1:800; cat. no. sc-13891, Santa Cruz Biotechnology, Inc.) and anti-E-cadherin (1:200; cat. no. sc-71009, Santa Cruz Biotechnology, Inc.). IHC analyses (mouse anti-goat IgG-HRP: cat. no. sc-2354, 1:2,000; m-IgGκ BP-HRP: cat. no. sc-516102, 1:2,000, Santa Cruz Biotechnology, Inc.) were performed as previously described (21) . A staining index (SI) score of ≥6 indicated high expression and an SI score of ≤4 indicated low expression (21) .
Western blot analysis. Western blot analysis was performed following a previously described protocol (22) . Protein was obtained using a lysis buffer (1% SDS, 10 mM Tris-HCl, pH 7.6, 20 µg/ml aprotinin, 20 µg/ml leupeptin and 1 mM AEBSF Cell proliferation, migration and invasion assays. Cell proliferation and migration were measured as previously described (23, 24) . Migration assays were performed using the microliter scale radial monolayer migration assay. Tumor cells (5x10 5 ) were seeded in 6-well plates and grown to confluence overnight. Twenty-four hours after incubation with 0.1% bovine serum albumin (BSA, Gibco; Thermo Fisher Scientific, Inc.) or 10 µg/ml laminin (cat. no. sc-29012, Santa Cruz Biotechnology, Inc.) conditions a line was scratched within the confluent cell layer using the fine end of a 10-ml pipette tip (time 0). Cells were washed with phosphate-buffered saline (PBS, Procell Inc., Wuhan, China) and photographed under a 20X objective lens every 6 h using an inverted Leica phase-contrast microscope (Leica DFC 300 FX, Leica Microsystems, Inc., Wetzlar, Germany). The invasiveness of cells was determined using a Transwell assay on a 24-well Transwell plate (8-µm pore size; Corning Inc., Corning, NY, USA). A total of 1x10 5 cells were plated in the top chamber. BD Matrigel™ Basement Membrane Matrix was added to the upper membrane and allowed to gel for 1 h. Subsequently, 500 µl medium containing chemotactic factor was placed in the lower chamber. Cells were plated in the upper chamber of quadruplicate wells at a density of 1x10 5 /ml and incubated for 24 h. Cells were then fixed with paraformaldehyde, stained with crystal violet (cat. no. sc-207460, Santa Cruz Biotechnology, Inc.), and counted immediately after staining.
Statistical analysis. The Predictive Analytics Software 18 software package (SPSS, Inc., Chicago, IL, USA) was used for statistical analyses. Data are presented as the means ± standard deviations (SD) of 3 independent experiments. The association between CCT8 expression and patient clinicopathological features was calculated using the χ 2 test. Kaplan-Meier methods were used to construct survival curves. Multivariate analysis was performed using the Cox proportional hazards model. One-way analysis of variance followed by Tukey's post hoc test was used to determine whether differences between groups were significant and P<0.05 was considered to indicate a statistically significant difference.
Results
CCT8 expression is associated with the clinicopathological variables of patients with ESCC.
CCT8 and E-cadherin expression in the 128 patients with ESCC was assessed using IHC. CCT8 expression ( Fig. 1 ) and its association with the clinicopathological variables of ESCC is presented in Tables I and II . Following a previously described protocol (22) , patients were divided into two groups: One group contained patients exhibiting high CCT8 expression (score ≥6) and one group contained patients exhibiting low CCT8 expression (score ≤4). The results demonstrated that CCT8 expression was associated with pathological grading (P<0.001), tumor depth (P<0.011) and LNM (P<0.001); however, it was not associated with other prognostic factors, including tumor size (Table I) . These results indicate that there is an association between CCT8 expression and the degree of ESCC malignancy. A total of 38 out of 57 (66.7%) patients in the high CCT8 expression group succumbed compared with only 22 of 71 (31.0%) patients in the low expression group (P<0.001; Table II) . Furhthermore, patients with poor pathological grading (P<0.001), LNM (P= 0.041), greater tumor depth (P= 0.035) and high E-cadherin expression (P= 0.004) exhibited significantly lower rates of survival (Table II) . Based on the level of CCT8 expression, the 128 patients were divided into two groups based on the level of CCT8 expression. Kaplan-Meier analysis indicated that patients exhibiting high expression of CCT8 had poorer overall survival rates. M, months; CCT8, chaperonin containing T-complex protein 1 subunit 8.
Survival status
Kaplan-Meier survival curves were then constructed to determine the survival rates of patients in the high CCT8 expression group compared with those in the low CCT8 expression group. The results indicated that the survival time of patients in the high CCT8 expression group was significantly lower than that of patients in the low CCT8 expression group (P<0.05; Fig. 2) . A multivariate Cox proportional hazards model was then used to predict patient survival. The results demonstrated that tumor pathological grade, LNM, tumor depth, CCT8 and E-cadherin expression were significant predictors of patient survival (P<0.05; Table III ).
CCT8 expression is increased in highly metastatic ESCC tissues.
As CCT8 expression is associated with LNM in ESCC, it was hypothesized that it may also be associated with the migration of ESCC cells. Therefore, the expression of CCT8 in ESCC tissues was evaluated (Fig. 3A) . CCT8 expression was high in tissues taken from patients with LNM and low in tissues from patients without LNM. In addition, CCT8 expression was measured in the TE-1, ECA109 and KYSE30 ESCC cell lines (Fig. 3B) . Quantification of the results indicated that TE-1 cells exhibited the highest level of CCT8 expression among the ESCC cell lines (Fig. 3C) ; therefore, TE-1 cells were used in subsequent experiments.
Actively migrating cells highly express CCT8. It was hypothesized that CCT8 expression is associated with tumor migration. A monolayer wound healing assay was used to assess the migration rate of cells plated onto the nonpermissive substrate BSA and the migration-stimulating substrate, laminin (24, 25) . It was demonstrated that laminin significantly increased the migration of TE-1 compared with those cells treated with BSA (P<0.05; Fig. 4A ). To determine whether the migratory phenotype affected cell proliferation, a Cell Counting Kit-8 (Dojindo Molecular Technologies, Inc., Kumamato, Japan) was used and the cell growth rate was determined. The results demonstrated that laminin stimulated TE-1 cell migration in vitro but did not affect cell proliferation (Fig. 4B) . When TE-1 cells were plated on laminin, CCT8 expression increased markedly, as did the expression of N-cadherin and vimentin; by contrast, the expression of E-cadherin markedly decreased (Fig. 4C) . These results suggest that CCT8 may serve a role in the migration of ESCC cells.
CCT8 promotes ESCC cell migration and invasion in vitro by regulating α-actin and β-tubulin.
To assess the function of CCT8 in ESCC cells, CCT8 expression was knocked down and western blotting was used to verify this loss of expression (Fig. 5A) . Three target sites were selected to knockdown CCT8 expression. The most significant decrease in CCT8 expression was following CCT8 knockdown with si#1 and si#2 (P<0.01 and P<0.05, respectively; Fig. 5B) ; therefore, these were used in subsequent studies. CCT8 knockdown also significantly inhibited the wound healing process (P<0.05; Fig. 5C and D) and significantly decreased the invasiveness of TE-1 cells (Fig. 5E and F) . CCT8 knockdown also markedly increased the expression of E-cadherin and decreased the expression of N-cadherin and vimentin (Fig. 5G) . Furthermore, expression of the apoptosis marker, cleaved caspase-3, was increased. It has been reported that CCT8 interacts with α-actin and β-tubulin, which can stimulate cell motility (26) . The results of western blotting demonstrated that α-actin and β-tubulin were markedly downregulated following CCT8 knockdown (Fig. 5G ). These observations suggest that CCT8 facilitates cell motility and is associated with the regulation of α-actin and β-tubulin.
CCT8 expression is closely associated with cisplatin-treated TE-1 cells.
Cisplatin is a chemotherapy drug widely used to treat different types of cancer, including ESCC (27); therefore, it was determined whether cisplatin downregulates CCT8 expression in ESCC. TE-1 cells treated with cisplatin for 48 h exhibited a dose-dependent decrease in CCT8 expression and a dose-dependent increase in cleaved caspase-3 expression (Fig. 6A) . α-actin and β-tubulin expression also decreased in a dose-dependent manner (Fig. 6A) . Cisplatin induced the upregulation of E-cadherin and decreased the expression of N-cadherin, vimentin, α-actin and β-tubulin. These effects were enhanced following CCT8 knockdown (Fig. 6B ). These data demonstrate that CCT8 knockdown significantly increases the apoptosis of TE-1 cells and enhanced the effects of cisplatin on such cells. 
Discussion
ESCC is a common malignancy affecting people across the world. LNM is an important prognostic indicator for patients with ESCC and may influence the treatments such patients receive. In the present study, CCT8 expression in 128 patients with ESCC was assessed and statistical analysis demonstrated that there was an association between CCT8 expression and LNM. Furthermore, the survival rates of patients with high CCT8 expression were significantly decreased compared with those exhibiting low CCT8 expression. Therefore, CCT8 expression may be a useful prognostic factor in determining the survival of patients with ESCC.
CCT is a cytosolic chaperonin that interacts with various cellular proteins (28) . CCT8 is a microtubule-associated protein (29) and Rademacher et al (30) demonstrated that CCT is involved in cytoskeletal rearrangements. Consequently, it was hypothesized that CCT8 may be associated with tumor cell migration. Cell migration serves an important role in several physiological processes, including wound healing, tissue morphogenesis and metastasis (31) . siRNAs were used to knockdown CCT8 expression and identify whether decreased CCT8 expression influences the motility of TE-1 cells. The results indicated that, following CCT8 knockdown, TE-1 cells exhibited decreased migratory and invasive abilities compared with normal cells. CCT8 knockdown also altered the expression of epithelial-Mesenchymal transition markers, including E-cadherin, N-cadherin and vimentin.
Previous studies have demonstrated that CCT8 is associated with cell proliferation in B-cell non-Hodgkin's lymphoma (16) , glioma (17) and hepatocellular carcinoma (18) . The results of the current study indicated that CCT8 knockdown induces cell death. Combination treatment of cisplatin with siCCT8 decreased the ability of ESCC cells to migrate and invade, thus inducing the death of ESCC cells. These data indicate that CCT8 serves an essential role in the migration and invasion of ESCC.
The microtubule, which is composed of α-actin and β-tubulin (26) is essential to cellular activities including cell division, polarization and migration (32) . Proteins associated with α-actin and β-tubulin serve a key role in particular cellular processes, and CCT8 is closely associated with α-actin and β-tubulin (33) (34) (35) . The results of the current study demonstrated that CCT8 knockdown decreased α-actin and β-tubulin expression in ESCC cells. It has been suggested that α-actin and β-tubulin act as natural substrates for CCT, indicating that the chaperone may serve an important role in maintaining the integrity of the cytoskeleton (36) . Hence, CCT gene mutations weaken α-actin-and β-tubulin-dependent structures (37) . However, the precise mechanism by which CCT8 stimulates the activity of α-actin and β-tubulin remains unknown. It has been demonstrated that CCT8 interacts with α-actin and β-tubulin (22) and the results of the current study demonstrated that CCT8 knockdown decreased the expression of α-actin and β-tubulin. It was suggested that the combination of CCT8 and α-actin or β-tubulin induced changes in the expression of α-actin and β-tubulin. This indicates that CCT8 forms a complex with α-actin and β-tubulin and subsequently stimulates the migration of ESCC. The CCT complex regulates many proteins; however, it is possible that the decreased migration and invasion of ESCC cells observed following CCT8 knockdown were due to the impaired function of other proteins as well as α-actin and β-tubulin. Further studies are required to investigate whether this is the case. Furthermore, the response of cells to cisplatin treatment following CCT8 knockdown indicated that CCT8 siRNA induces the death of ESCC cells due to the combined regulation of α-actin and β-tubulin by CCT8 and cisplatin. This indicates that CCT8 promotes the migration and invasion of ESCC cells by activating the expression of α-actin and β-tubulin.
The two primary predictors for the survival of patients with malignant tumors are uncontrolled growth and invasiveness. However, no association between CCT8 expression and tumor size was observed in the current study. Furthermore, the cohort size was small and studies involving a larger number of patients are required to ensure that these results can be replicated. Future studies, including randomized controlled trials, are required to validate the results of the current study.
In conclusion, the present study demonstrated that CCT8 enhanced the migration and invasion of ESCC cells, indicating that ectopic CCT8 expression contributes to the highly aggressive nature of ESCC. This stimulatory effect of CCT8 on cell migration and invasion was accomplished by increasing α-actin and β-tubulin expression. These results demonstrate that CCT8 is a critical factor in the migration and invasion of ESCC cells. Given that CCT8 expression is widely upregulated in ESCC, CCT8 silencing may be a promising method of preventing and treating the metastasis of ESCC cells.
